Printer Friendly

Pancreatic cancer research.

An experimental drug for advanced pancreatic cancer shows promise in Phase III testing. After recent evaluation of safety data, study of the anticancer drug Virulizin is continuing as planned, according to Lorus Therapeutics Inc., the drug's manufacturer.

The trial, involving 436 patients at over 100 clinical sites in North America, South America, and Europe, is expected to conclude in mid-2005.

Other data show no significant adverse interactions between Virulizin and the current standard of care in pancreatic cancer, gemcitabine. Virulizin stimulates a patient's immune system to attack tumors. In contrast to most standard chemotherapeutic drugs, Virulizin was well tolerated in preliminary research.
COPYRIGHT 2005 Benjamin Franklin Literary & Medical Society, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Medical Update
Article Type:Brief Article
Geographic Code:1CANA
Date:Mar 1, 2005
Words:102
Previous Article:Curry: spice of life.
Next Article:Do you need a low-vision exam?
Topics:


Related Articles
New pancreatic cancer gene identified.
New treatments hold hope for pancreatic cancer patients.
THE POST INVESTIGATES THE PANCREAS.
CLUES TO PANCREATIC CANCER.
CT scans for pancreatic cancer.
Lustgarten event to bet on research.
Folate.
Kalmon and Neil Dolgin get thank you from group.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters